MEDI 560Alternative Names: MEDI-560; PIV-3 vaccine - MedImmune (AstraZeneca); rHPIV3cp45
Latest Information Update: 25 Mar 2017
At a glance
- Originator MedImmune
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Parainfluenza virus infections
Most Recent Events
- 01 Dec 2008 Phase-I/IIa development is ongoing in USA
- 26 Jul 2007 Phase-I clinical trials in Parainfluenza virus infections in USA (Intranasal)